Experimental therapies with novel compounds in prostate cancer

Poster Session 04

Location: Room 14c (ICM, Level 1)
Chairs: F. Claessens, Leuven (BE)
        T.B. Lam, Aberdeen (GB)
        F.R. Santer, Innsbruck (AT)

Aims and objectives of this presentation
Clinical relevance of experimental therapy studies will be discussed and clinical relevance assessed. Targeting tumour metabolism is a novel innovative strategy for prostate cancer. The potential of novel compounds will be presented in the session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*38

Preventing occurrence of metastatic disease in rats with locally advanced prostate cancer by immunomodulation and vascular targeted therapy
By: Lindner U.¹, Preise D.², Kudnova N.³, Agaronov A.¹, Salomon Y.³, Coleman J.⁴, Leibovich D.¹
Institutes: Kaplan Medical Center, Dept. of Urology, Rehovot, Israel, ²The Weizmann Institute of Science, Dept. of Plant and Environmental Sciences, Rehovot, Israel, ³The Weizmann Institute of Science, Dept. of Biological Regulation, Rehovot, Israel, ⁴Memorial Sloan-Kettering Cancer Center, Dept. of Surgery, New York, United States of America

*39

Targeting cell metabolism to improve prostate cancer therapeutics
By: Bedai M., Rao K., Robson C., McCracken S.
Institutes: Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom

*40

Efficacy of prostate cancer compound with novel mechanism of action targeting the DNA binding domain of the androgen receptor
By: Borgmann H., Dalal K., Beraldi E., Cherkasov A., Rennie P., Gleave M.
Institutes: Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

*41

The role of the HER2 and HER3 in prostate cancer and their potential as therapeutic targets
By: Rao K., Alsamraee M., Gaughan L., Robson C., McCracken S.
Institutes: Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom

*42

Targeting clusterin-associated proteins improve cellular sensitivity to taxane in prostate cancer
By: Takeuchi A., Shiota M., Katsunori T., Inokuchi J., Kashiwagi E., Dejima T., Yokomizo A., Eto M.
Institutes: Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan

*43

Equol, a metabolite converted from daidzein by enterobacteria, has chemopreventive and inhibitory effects against prostate cancer
By: Tatsumi Y.¹, Miyake M.², Hori S.², Morizawa Y.², Nakai Y.², Anai S.², Torimoto K.², Fujii T.¹, Konishi N.¹, Fujimoto K.²
Institutes: Nara Medical University, Dept. of Pathology, Kashihara, Japan, ²Nara Medical University, Dept. of Urology, Kashihara, Japan

*44

Allyl isothiocyanate induces reactive oxygen species-mediated autophagy through beclin-1 in

Scientific Programme
human prostate cancer cells
By: Chen H-E., Lin J-F., Lin Y-C., Tsai T-F., Chou K-Y., Hwang T.I.S.
Institutes: Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan

*45
Simvastatin inhibits the proliferation, migration and invasion of androgen independent human prostate cancer cells via up-regulation of Annexin A10
Institutes: Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan

*46
Ability of plant extracts to reactivate epigenetically silenced genes in prostate cancer cells
By: Schagdarsurengin U., Teuchert L., Nesheim N., Wagenlehner F., Dansranjavin T.
Institutes: Justus Liebig University of Giessen, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany

*48
Development of the first model of radical prostatectomy in mouse: A feasibility study with biochemical validation
Institutes: Urological Research Institute, Ircss San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy

09:43 - 09:50
Summary and context
F. Claessens, Leuven (BE)